DeepLook Medical, a women’s health technology company advancing medical imaging through AI-powered visual enhancement, has announced the commercial deployment of its flagship platform, DL Precise, at several leading healthcare institutions including Cleveland Clinic, Mayo Clinic, AdventHealth, and Geisinger.
The FDA-cleared technology from DeepLook Medical specifically addresses challenges in detecting lesions in dense breast tissue, where traditional mammography can miss up to 50% of cancers. According to the company, over 40% of women have dense breast tissue and face a higher risk of breast cancer.
“The commercial adoption of DL Precise at major institutions across the country marks a pivotal moment for DeepLook Medical,” said Marissa Fayer, CEO of DeepLook Medical. “These installations reflect not only a growing demand for enhanced imaging precision but also confidence in the value we’re delivering, especially in areas where traditional imaging falls short.”
DeepLook’s platform integrates directly into existing radiology workstations and uses proprietary shape-recognition AI to provide single-click segmentation and enhanced visualization of suspicious lesions. Currently compatible with mammography, ultrasound, CT, and MRI, the technology is now expanding into broader ultrasound applications.
The adoption comes following the recent FDA mandate requiring mammography facilities to notify patients about breast density, highlighting the need for advanced detection tools. According to preliminary data from a New York metropolitan hospital, use of DeepLook’s software was associated with a 12% improvement in recall performance aligned with American College of Radiology guidelines.
“Healthcare systems around the world are proactively embracing AI not just as a future promise, but as a present-day solution to long-standing diagnostic challenges,” said Charlotte Owens, MD, FACOG, Chief Medical Officer of DeepLook Medical. “With DL Precise, we’re seeing firsthand how intelligent imaging can immediately enhance clinical decision-making, reduce variability, and bring clarity to some of the most complex cases, especially in dense tissue where traditional tools often fall short.”
To further evaluate the platform’s impact, DeepLook Medical has launched evidence-generation studies in the United States, United Kingdom, and Israel. The company recently relocated to Arizona and is supported by distribution partners including Barco, as well as investors such as Arizona Venture Capital Inc.
